## Accepted Manuscript

Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Ville Vartiainen, Janne Raula, Luis M. Bimbo, Jenni Viinamäki, Janne T. Backman, Nurcin Ugur, Esko Kauppinen, Eva Sutinen, Emmi Joensuu, Katri Koli, Marjukka Myllärniemi


PII: S0378-5173(18)30232-1

DOI: https://doi.org/10.1016/j.ijpharm.2018.04.019

Reference: IJP 17426

To appear in: International Journal of Pharmaceutics

Received Date: 14 January 2018 Revised Date: 9 April 2018 Accepted Date: 10 April 2018



Please cite this article as: V. Vartiainen, J. Raula, L.M. Bimbo, J. Viinamäki, J.T. Backman, N. Ugur, E. Kauppinen, E. Sutinen, E. Joensuu, K. Koli, M. Myllärniemi, Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice, *International Journal of Pharmaceutics* (2018), doi: https://doi.org/10.1016/j.ijpharm.2018.04.019

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **ACCEPTED MANUSCRIPT**

Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Ville Vartiainen<sup>a,c.\*</sup>, Janne Raula<sup>b</sup>, Luis M. Bimbo<sup>e</sup>, Jenni Viinamäki<sup>f</sup>, Janne T. Backman<sup>f</sup>, Nurcin Ugur<sup>b</sup>, Esko Kauppinen<sup>b</sup>, Eva Sutinen<sup>a</sup>, Emmi Joensuu<sup>c</sup>, Katri Koli<sup>c,†</sup> and Marjukka Myllärniemi<sup>d,†</sup>

<sup>a</sup> Department of Clinical Medicine, Division of Pulmonary Medicine, University of Helsinki, Finland

<sup>b</sup> Department of Applied Physics, Aalto University School of Science, Finland

<sup>c</sup> Research Programs Unit, Translational Cancer Biology, University of Helsinki, Finland

<sup>d</sup> University of Helsinki and Helsinki University Hospital, Heart and Lung Center and HUH

Diagnostics, Pulmonary Medicine, Finland

<sup>e</sup> Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, United

Kingdom, and Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy,

University of Helsinki, Finland

f Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital,

Finland

† These authors contributed equally

\*Corresponding author: Ville Vartiainen, Haartmaninkatu 3, 00014 Helsinki, Finland, Phone

+358504306414, E-mail ville.vartiainen@helsinki.fi

20

5

10

15

**Keywords:** idiopathic pulmonary fibrosis, antifibrotics, tilorone, dry powder inhaler

## Download English Version:

## https://daneshyari.com/en/article/8519846

Download Persian Version:

https://daneshyari.com/article/8519846

<u>Daneshyari.com</u>